We next chose chemotherapeutic medicines, BRAF/MEK inhibitors (Dabrafenib, Trametinib) and immunotherapy drugs (pembrolizumab, nivolumab, ipilimumab) that are already used to treat melanoma to assess the sensitivities of individuals in the low- and high-risk categories to these medications. The gene discussed is BRAF; the disease is melanoma.